NDAORALTABLET
Approved
May 2004
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Mechanism of Action
Pharmacologic Class:
Rifamycin Antibacterial
Clinical Trials (5)
Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea
Started Dec 2025
Rifaximin SSD in Dementia Trial
Started Dec 2024
Rifaximin for the Secondary Prevention of Recurrent Pouchitis
Started Jul 2024
Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis
Started Aug 2022
Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation
Started Jul 2022
Loss of Exclusivity
LOE Date
Oct 2, 2029
43 months away
Patent Expiry
Oct 2, 2029